Progyny (PGNY) Stock Forecast & Price Target

Progyny is viewed favorably because its integrated fertility platform combines Smart Cycles, a high-quality specialist network, Progyny Rx, and patient care advocates to drive measurably better clinical outcomes and a more efficient cost structure than traditional, capped-benefit alternatives. The company’s fundamentals are reinforced by retention above 99%, more than 600 clients and 7.5M members, a win rate above 50% on evaluated deals, and 1Q26 results that exceeded consensus on both revenue and EBITDA while adjusted gross margin improved to 27.2%. Its outlook is further supported by a deep growth runway in a largely underpenetrated market of roughly 105M self-insured lives and about 50M fully insured lives, plus regulatory and commercial catalysts such as California Senate Bill 729, the CalPERS partnership effective July 1, 2027, and a stronger-than-typical start to the selling season.

Progyny is fundamentally challenged by a combination of slower-than-expected growth visibility and fragile demand assumptions, as management acknowledged that some early-renewing clients did not prioritize fertility benefits this year, new solution revenue may materialize more slowly than modeled, and eligible lives were lowered, which has already pressured sentiment. The company’s 2026 guide of $1.365B-$1.405B in revenue and $232M-$244M in EBITDA still depends on modest utilization assumptions of 0.93-0.95 cycles per female utilizer and a 1.04%-1.05% female utilization rate, while risks from higher attrition, utilization pressure, an economic downturn, and political uncertainty around reproductive rights could weigh on membership and employer adoption. Even though Progyny cites a differentiated network, healthcare integration, and 99% client retention excluding the Amazon event, the stock’s negative outlook is anchored in the possibility that the moat is not translating into enough incremental utilization or new business acceleration to offset slower revenue realization and elevated sentiment risk.